The company had two approved products: EGRIFTA (marketed in Canada and the United States) and Trogarzo (approved for commercialization in the United States). In October 2023, the company reduced R&D activities with plans to pursue future clinical research in oncology and NASH through partnership deals.
Cyborg Score Rationale
The company faced significant operational headwinds before acquisition, including R&D restructuring, narrowed geographic focus, and pipeline consolidation. The acquisition by Future Pak suggests the standalone business model became unsustainable.
Top Insights
Acquisition completed in September 2025 marks end of public company status; company is now private subsidiary of Future Pak
Pipeline narrowed significantly; shifted from multi-therapeutic approach to HIV-centric commercialization
Organizational restructuring in late 2023 reduced R&D headcount by up to 25 positions to achieve profitability
Limited geographic presence post-2022 (exited European operations); concentrated on North American markets
Named Competitors
Bictegravir/TAF — HIV integrase inhibitor-based therapy
ViiV Healthcare Portfolio — HIV treatment and management therapies
Trogarzo Alternative — Multidrug-resistant HIV treatments
Recent Developments
(September 2025) Acquired by Future Pak affiliate CB Biotechnology for US$3.01 per share plus contingent value rights
(October 2023) Restructured R&D operations and reduced workforce by up to 25 positions
(April 2022) Exited European commercialization; focused exclusively on North American territory
Open the full interactive Theratechnologies Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.